

Tae-You Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11448218/publications.pdf>

Version: 2024-02-01

119
papers

20,537
citations

28736

57
h-index

21843

118
g-index

120
all docs

120
docs citations

120
times ranked

24562
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 76, 862-873.	1.8	568
2	Abstract 2800: Use of an optimized machine learning algorithm to develop DNA methylation markers for detecting colorectal cancer (CRC). <i>Cancer Research</i> , 2022, 82, 2800-2800.	0.4	0
3	Abstract 5157: ctDNA change predicts treatment outcome of regorafenib in metastatic colorectal cancer. <i>Cancer Research</i> , 2022, 82, 5157-5157.	0.4	0
4	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2021, 27, 713-718.	3.2	27
5	Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. <i>British Journal of Cancer</i> , 2021, 125, 200-208.	2.9	22
6	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. <i>Liver International</i> , 2021, 41, 2759-2767.	1.9	5
7	Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 569-577.	3.7	50
8	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 991-1001.	5.1	179
9	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2991-3001.	0.8	257
10	Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 98-107.e1.	1.1	15
11	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. <i>JAMA Oncology</i> , 2020, 6, e204564.	3.4	746
12	Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing. <i>PLoS ONE</i> , 2020, 15, e0232754.	1.1	19
13	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 382, 1894-1905.	13.9	3,828
14	Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 122, 1630-1637.	2.9	472
15	Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 328-339.	4.5	32
16	A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01). <i>Oncologist</i> , 2019, 24, 18-e24.	1.9	25
17	Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 510-518.	1.3	39
18	Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3111-3123.	0.8	100

#	ARTICLE	IF	CITATIONS
19	Targeted next-generation DNA sequencing identifies Notch signaling pathway mutation as a predictor of radiation response. <i>International Journal of Radiation Biology</i> , 2019, 95, 1640-1647.	1.0	2
20	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. <i>Journal of Hepatology</i> , 2019, 71, 543-552.	1.8	180
21	Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 223-239.	1.3	13
22	Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells. <i>Molecular Oncology</i> , 2018, 12, 1398-1409.	2.1	10
23	Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 164-174.	2.7	13
24	Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system. <i>British Journal of Cancer</i> , 2017, 116, 1012-1020.	2.9	40
25	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet, The</i> , 2017, 389, 2492-2502.	6.3	3,224
26	Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy. <i>Oncotarget</i> , 2017, 8, 79441-79452.	0.8	26
27	Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis. <i>Cancer Research and Treatment</i> , 2017, 49, 643-655.	1.3	18
28	Identification of Diverse Adenosine-to-Inosine RNA Editing Subtypes in Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 1077-1087.	1.3	22
29	Therapeutic implication of HER2 in advanced biliary tract cancer. <i>Oncotarget</i> , 2016, 7, 58007-58021.	0.8	63
30	Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. <i>BMC Cancer</i> , 2016, 16, 515.	1.1	11
31	Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients. <i>Clinical Epigenetics</i> , 2016, 8, 36.	1.8	14
32	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. <i>Breast Cancer Research</i> , 2015, 17, 33.	2.2	138
33	Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. <i>PLoS ONE</i> , 2015, 10, e0139749.	1.1	183
34	Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2015, 21, 1457.	1.4	98
35	Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System. <i>Materials</i> , 2015, 8, 519-534.	1.3	6
36	Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy. <i>PLoS ONE</i> , 2015, 10, e0138728.	1.1	14

#	ARTICLE	IF	CITATIONS
37	Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2015, 47, 607-615.	1.3	93
38	The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 3376-88.	1.4	6
39	Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors. <i>Journal of Korean Medical Science</i> , 2014, 29, 1094.	1.1	22
40	RNA editing in <i>RHOQ</i> promotes invasion potential in colorectal cancer. <i>Journal of Experimental Medicine</i> , 2014, 211, 613-621.	4.2	97
41	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1224-1235.	5.1	1,932
42	Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 1245-1253.	5.1	336
43	Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 767-774.	5.1	713
44	The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy. <i>Journal of Pain and Symptom Management</i> , 2014, 48, 13-25.	0.6	17
45	RNA Editing in <i>RHOQ</i> Promotes Invasion Potential in Colorectal Cancer. <i>Journal of Cell Biology</i> , 2014, 204, 2047OIA60.	2.3	1
46	OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. <i>Cancer Letters</i> , 2013, 335, 145-152.	3.2	100
47	Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. <i>Experimental and Molecular Medicine</i> , 2013, 45, e64-e64.	3.2	51
48	Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 16-26.	1.9	57
49	RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 865-877.	1.9	116
50	Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing. <i>PLoS ONE</i> , 2013, 8, e64271.	1.1	71
51	Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 439-451.	1.9	62
52	Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. <i>Anti-Cancer Drugs</i> , 2012, 23, 288-297.	0.7	21
53	Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers. <i>Laboratory Investigation</i> , 2012, 92, 1033-1044.	1.7	34
54	The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. <i>Investigational New Drugs</i> , 2012, 30, 2148-2160.	1.2	15

#	ARTICLE	IF	CITATIONS
55	Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells. <i>Cancer Letters</i> , 2012, 316, 77-84.	3.2	8
56	Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer. <i>Cancer Letters</i> , 2012, 321, 128-136.	3.2	12
57	<i>ALU</i> and <i>LINE1</i> hypomethylations in multistep gastric carcinogenesis and their prognostic implications. <i>International Journal of Cancer</i> , 2012, 131, 1323-1331.	2.3	71
58	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. <i>Journal of Neuro-Oncology</i> , 2012, 106, 303-313.	1.4	64
59	Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. <i>Cancer Letters</i> , 2011, 302, 155-165.	3.2	47
60	Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. <i>Breast Cancer Research</i> , 2011, 13, R22.	2.2	187
61	17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 799-804.	0.8	4
62	Antitumor activity of NVP–AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. <i>Cancer Science</i> , 2011, 102, 1388-1395.	1.7	46
63	High serum TGF- β predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 107-114.	1.1	21
64	Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes. <i>Cellular Oncology (Dordrecht)</i> , 2011, 34, 45-54.	2.1	7
65	Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. <i>BMC Cancer</i> , 2011, 11, 452.	1.1	61
66	Clinicopathologic Characteristics of Patients With Stage III/IV (M0) Advanced Gastric Cancer, According to HER2 Status Assessed by Immunohistochemistry and Fluorescence In Situ Hybridization. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 94-100.	2.1	31
67	Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 320-325.	0.5	54
68	Inhibition of Histone Deacetylase 10 Induces Thioredoxin-Interacting Protein and Causes Accumulation of Reactive Oxygen Species in SNU-620 Human Gastric Cancer Cells. <i>Molecules and Cells</i> , 2010, 30, 107-112.	1.0	66
69	Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less. <i>BMC Cancer</i> , 2010, 10, 557.	1.1	48
70	<i>KRAS</i> mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach. <i>Molecular Carcinogenesis</i> , 2010, 49, 353-362.	1.3	116
71	Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy. <i>Journal of Korean Medical Science</i> , 2009, 24, 910.	1.1	20
72	Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2. <i>PLoS ONE</i> , 2009, 4, e5933.	1.1	91

#	ARTICLE	IF	CITATIONS
73	Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2526-2536.	1.9	65
74	Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 153-160.	1.1	41
75	Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer. <i>Annals of Surgical Oncology</i> , 2009, 16, 1112-1121.	0.7	76
76	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. <i>Lung Cancer</i> , 2009, 65, 80-84.	0.9	118
77	Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2009, 65, 204-207.	0.9	29
78	Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. <i>Journal of Molecular Medicine</i> , 2008, 86, 117-128.	1.7	45
79	Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers. <i>Laboratory Investigation</i> , 2008, 88, 153-160.	1.7	36
80	ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 60, 401-407.	0.9	78
81	Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment. <i>Lung Cancer</i> , 2008, 61, 30-34.	0.9	89
82	Overexpression of A-kinase anchoring protein 12A activates sterol regulatory element binding protein-2 and enhances cholesterol efflux in hepatic cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 2534-2543.	1.2	6
83	The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. <i>Cancer Letters</i> , 2008, 272, 296-306.	3.2	111
84	Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. <i>Biochemical and Biophysical Research Communications</i> , 2008, 368, 318-322.	1.0	89
85	A-kinase anchoring protein 12 regulates the completion of cytokinesis. <i>Biochemical and Biophysical Research Communications</i> , 2008, 373, 85-89.	1.0	13
86	Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. <i>Lung Cancer</i> , 2008, 59, 111-118.	0.9	91
87	STAT3 inhibits the degradation of HIF-1 α by pVHL-mediated ubiquitination. <i>Experimental and Molecular Medicine</i> , 2008, 40, 479.	3.2	103
88	Transcriptional induction of DLC-1 gene through Sp1 sites by histone deacetylase inhibitors in gastric cancer cells. <i>Experimental and Molecular Medicine</i> , 2008, 40, 639.	3.2	15
89	Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 607-615.	1.9	50
90	Enzastaurin, a Protein Kinase C β Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells. <i>Cancer Research</i> , 2008, 68, 1916-1926.	0.4	66

#	ARTICLE	IF	CITATIONS
91	Aggressiveness of Cancer-Care near the End-of-Life in Korea. Japanese Journal of Clinical Oncology, 2008, 38, 381-386.	0.6	94
92	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. Expert Review of Molecular Diagnostics, 2007, 7, 821-836.	1.5	12
93	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. Pharmacogenetics and Genomics, 2007, 17, 313-319.	0.7	54
94	DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2007, 355, 72-77.	1.0	74
95	Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. Journal of Molecular Medicine, 2007, 85, 1137-1148.	1.7	58
96	First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy ± radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leukemia and Lymphoma, 2006, 47, 1274-1282.	0.6	54
97	Epidermal Growth Factor Receptor Mutations and Response to Chemotherapy in Patients with Non-Small-Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2006, 36, 344-350.	0.6	29
98	Gefitinib for refractory advanced non-small-cell lung cancer. Lancet, The, 2006, 367, 299-300.	6.3	10
99	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Lung Cancer, 2006, 54, 201-207.	0.9	35
100	Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Molecular Cancer Therapeutics, 2006, 5, 3085-3095.	1.9	99
101	CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience. Supportive Care in Cancer, 2006, 14, 103-108.	1.0	65
102	Histone Deacetylase Inhibitors for Cancer Therapy. Epigenetics, 2006, 1, 15-24.	1.3	61
103	Epigenomic Profiling Reveals Novel and Frequent Targets of Aberrant DNA Methylation-Mediated Silencing in Malignant Glioma. Cancer Research, 2006, 66, 7490-7501.	0.4	153
104	Optimization of Patient Selection for Gefitinib in Non-Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation. Clinical Cancer Research, 2006, 12, 2538-2544.	3.2	245
105	Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. Anticancer Research, 2006, 26, 3429-38.	0.5	17
106	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non-small cell lung cancer. International Journal of Cancer, 2005, 113, 109-115.	2.3	152
107	The Endogenous Ratio of Smad2 and Smad3 Influences the Cytostatic Function of Smad3. Molecular Biology of the Cell, 2005, 16, 4672-4683.	0.9	68
108	Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib. Journal of Clinical Oncology, 2005, 23, 2493-2501.	0.8	736

#	ARTICLE	IF	CITATIONS
109	Class I Histone Deacetylase-Selective Novel Synthetic Inhibitors Potently Inhibit Human Tumor Proliferation. <i>Clinical Cancer Research</i> , 2004, 10, 5271-5281.	3.2	139
110	The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor β -negative breast cancer cells to tamoxifen. <i>Oncogene</i> , 2004, 23, 1724-1736.	2.6	152
111	Aberrant methylation of integrin $\beta 4$ gene in human gastric cancer cells. <i>Oncogene</i> , 2004, 23, 3474-3480.	2.6	51
112	AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. <i>Oncogene</i> , 2004, 23, 7095-7103.	2.6	89
113	A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma. <i>Cancer</i> , 2004, 101, 2516-2522.	2.0	14
114	Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. <i>Oncogene</i> , 2003, 22, 3943-3951.	2.6	104
115	Synthesis and Biological Evaluation of 3-(4-Substituted-phenyl)-N-hydroxy-2-propenamides, a New Class of Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 5745-5751.	2.9	49
116	Comparison of Intrathecal Chemotherapy for Leptomeningeal Carcinomatosis of a Solid Tumor: Methotrexate Alone Versus Methotrexate in Combination with Cytosine Arabinoside and Hydrocortisone. <i>Japanese Journal of Clinical Oncology</i> , 2003, 33, 608-612.	0.6	75
117	Therapeutic Outcome of Extranodal NK/T-Cell Lymphoma Initially Treated with Chemotherapy Result of Chemotherapy in NK/T-Cell Lymphoma. <i>Acta Oncologica</i> , 2003, 42, 779-783.	0.8	74
118	Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1 α in gastric cancer cells. <i>Clinical Cancer Research</i> , 2003, 9, 433-40.	3.2	72
119	Ubiquitination of hypoxia-inducible factor requires direct binding to the $\beta 2$ -domain of the von Hippel-Lindau protein. <i>Nature Cell Biology</i> , 2000, 2, 423-427.	4.6	1,423